NY-ESO-1 (157-165) C165V – SLLMWITQV – General analogue epitope of tumor cells
HLA-A*02 Major Histocompatibility Complex (MHC) allele
HLA-A*02 allele is expressed in class I Human MHC Leukocyte Antigens (HLA),that are cell surface receptors,presenting peptides to the immune system. If a non-self-peptide is recognized by cytotoxic T-cells in the blood,cell death will be initiated via apoptosis.
NY-ESO-1 protein
Peptides presented by MHC class I molecule,are usually between 7 and 11 amino acids,originating from proteins expressed by the cell. SLLMWITQV peptide differes from the New York esophageal squamous cell carcinoma 1 (NY-ESO-1 : UniProt – P78358) native SLLMWITQC peptide,whose protein is part of a well-characterized group of cancer/testis antigens (CTAs).
Normally,NY-ESO-1 expression is restricted to germ cells and placental cells. However it is also expressed in 82% of neuroblastomas and 46% of melanomas,as well as in many other solid tumors and hematological malignancies.
NY-ESO-1 (157-165) C165V peptide application
Class I HLA molecules of the cancerous cells cited above present peptides from NY-ESO-1 protein,including SLLMWITQC,that binds the binding cleft of the HLA-A*0201 complex. NY-ESO-1 being the most immunogenic among the CTA family members,its peptides constitute attractive targets for specific immunotherapies and the stimulation of human NY-ESO-1 specific CD8+ T cells.
In order to better stimulate specific cytotoxic T-cells in PBMCs and analyze by ELISPOT peptide epitope,specificity,and cytokine production,like IFN-γ,SLLMWITQV variant peptide was used,as it is known to have a higher affinity for the binding cleft of the HLA-A*0201 complex than the native peptide. Moreover,SLLMWITQV has been used with adjuvant in protein nanoparticles in order to study cell-mediated immune responses and is also used in clinical trial to study the immunological effects of vaccines containing NY-ESO-1 (157-165) C165V.
SB-PEPTIDE also offers NY-ESO-1 (157-165) native peptide,as well as NY-ESO-1 (157-165) C165V biotinylated and scrambled versions.
Technical specifications
![]() |
Sequence : SLLMWITQV |
![]() |
MW : 1090 ,34 g/mol (C51H83N11O13S) |
![]() |
Purity : > 95% |
![]() |
Counter-Ion : TFA Salts (see option TFA removal) |
![]() |
Delivery format : Freeze dried in propylene 2mL microtubes |
![]() |
Peptide Solubility Guideline |
![]() |
Bulk peptide quantities available |
Price
| Product catalog | Size | Price € HT | Price $ HT |
| SB062-1MG | 1 mg | 88 | 110 |
| SB062-5MG | 5 mg | 308 | 385 |
| SB062-10MG | 10 mg | 522 | 653 |
| SB062-50MG | 50 mg | 1815 | 2268 |
References







